Johnson & Johnson To Host Investor Conference Call on Phase 3 COVID-19 Vaccine Results Transcript
Good morning, and welcome to Johnson & Johnson's Investor Webcast. (Operator Instructions) This call is being recorded. If anyone has any objections, you may disconnect at this time. (Operator Instructions) I would now like to turn the conference call over to Johnson & Johnson. You may begin.
Good morning. This is Chris DelOrefice, Vice President of Investor Relations for Johnson & Johnson. Welcome to this webcast as we are pleased to review our Phase III ENSEMBLE study results of our investigational single-dose COVID-19 vaccine candidate. Joining me on today's call is Mathai Mammen, Global Head of Janssen Research and Development.
A few logistics before we get into the details. This review is being made available via webcast, accessible through the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. This webcast may contain forward-looking statements, including statements about our investigational single-dose COVID-19 vaccine candidate. The viewer is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |